A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: Primary results of the ARISE trial

被引：0
|
作者：
Ashina, M. [1 ,2 ]
Dodick, D. [3 ]
Kudrow, D. [4 ]
Lanteri-Minet, M. [5 ,6 ]
Osipova, V.
Palmer, K. [7 ]
Picard, H. [8 ]
Mikol, D. [8 ]
Lenz, R. [8 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Rigshosp Glostrup, Fac Med & Hlth Sci, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Neurol, Rigshosp Glostrup, Fac Med & Hlth Sci, Copenhagen, Denmark
[3] Mayo Clin, Scottsdale, AZ USA
[4] Calif Med Clin Headache, Santa Monica, CA USA
[5] CHU, Pain Dept, Nice, France
[6] CHU, FHU InovPain, Nice, France
[7] Amgen Inc, Cambridge, England
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PR1045
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [1] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial
    Dodick, David
    Ashina, Messoud
    Kudrow, David
    Lanteri-Minet, Michel
    Osipova, Vera
    Paler, Kerry
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E98 - E98
  • [2] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and afety of Erenumab in Migraine Prevention: Primary Results of the ARISE Trial
    Dodick, D. W.
    Ashina, M.
    Kudrow, D.
    Lanteri-Minet, M.
    Osipova, V
    Palmer, K.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 191 - 192
  • [3] A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE ARISE TRIAL
    Dodick, David
    Ashina, Messoud
    Kudrow, David
    Lanteri-Minet, Michel
    Osipova, Vera
    Palmer, Kerry
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [4] Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: primary results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 117 - 117
  • [5] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 128 - 129
  • [6] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, Peter
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E104 - E104
  • [7] PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN MIGRAINE PREVENTION: PRIMARY RESULTS OF THE STRIVE TRIAL
    Goadsby, Peter J.
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [8] Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: Primary results of the STRIVE trial
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel D.
    Lenz, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [9] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
    Tepper, S. J.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. L.
    Silberstein, S. D.
    Winner, P.
    Leonardi, D. K.
    Mikol, D. D.
    HEADACHE, 2017, 57 : 130 - 130
  • [10] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
    Tepper, S.
    Widnell, K.
    Dolezil, D.
    Ashina, M.
    Reuter, U.
    Brandes, J. Lewis
    Silberstein, S.
    Winner, P.
    Leonardi, D.
    Mikol, D.
    CEPHALALGIA, 2016, 36 : 44 - 45
12345